Ovarian Cancer

Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress

The FDA has granted priority review to the supplemental biologics license application seeking the conversion of the accelerated approval of mirvetuximab soravtansine-gynx in patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who previously received 1 to 3 lines of systemic treatment to full approval.

The FDA granted breakthrough device designation to the ACR-368 OncoSignature assay for the identification of patients with ovarian cancer who may derive benefit from the CHK1/2 inhibitor ACR-368.

Hope Cottrill, MD, highlights key points that were presented at a State of the Science Summit meeting, including the role of bevacizumab plus PARP inhibitors in ovarian cancer management, how to manage adverse events associated with antibody-drug conjugates, and ongoing research in ovarian cancer risk reduction.

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

The European Commission has approved rucaparib as first-line maintenance therapy for patients with advanced ovarian cancer, regardless of BRCA mutation status, who have responded following the completion of frontline platinum-based chemotherapy.

The emerging CDH6-directed antibody-drug conjugate raludotatug deruxtecan had a manageable safety profile, generated pharmacokinetic activity, and produced early evidence of clinical response in patients with heavily pretreated, platinum-resistant ovarian cancer.

The use of olaparib as a monotherapy or in combination with cediranib did not provide a statistically significance overall survival benefit compared with standard-of-care platinum-based chemotherapy in patients with recurrent, platinum-sensitive ovarian cancer.

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

Expert oncologist Premal Thaker, MD, MS, reviews the current treatment landscape for recurrent low-grade serous ovarian cancer and considers the respective roles of various targeted agents in this setting.

The European Medicines Agency has accepted a marketing authorization application seeking the approval of mirvetuximab soravtansine-gynx for the treatment of patients with folate receptor alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

S. Alex Mastroyannis, MD, MSCE, discusses the management of gynecologic cancers, such as metastatic or recurrent ovarian and endometrial cancers.

Patients with recurrent ovarian cancer did not experience a statistically significant improvement in clinical outcomes such as progression-free survival and objective response rate with the addition of atezolizumab to chemotherapy and niraparib maintenance therapy.

Maintenance therapy consisting of single-agent senaparib reduced the risk of progression or death vs placebo in patients with newly diagnosed advanced ovarian cancer, irrespective of BRCA mutation status.

Expert perspectives from Shannon Westin, MD, MPH, FACOG, on frontline treatment options for patients with newly diagnosed low-grade serous ovarian cancer in the context of recent clinical trial data. Dr. Westin discusses optimizing treatment strategies while prioritizing quality of life and fertility preservation for patients.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the approval of a Type II variation application for rucaparib as a frontline maintenance in patients with advanced ovarian cancer who have responded to first-line, platinum-based chemotherapy, irrespective of BRCA mutational status.

Brian M. Slomovitz, MD, discusses the optimal role for PARP inhibition in patients with ovarian cancer, highlighting its efficacy in those harboring BRCA mutations.

The combination of the novel MCT inhibitor CYT-0851 and capecitabine displayed clinical activity and a tolerable safety profile in patients with advanced platinum-resistant ovarian cancer.

The FDA has granted fast track designation to AVB-001 for the treatment of adult patients with relapsed/refractory, platinum-resistant, high-grade serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.

Treatment with the interleukin-12 gene-mediated immunotherapy IMNN-001 in combination with neoadjuvant platinum chemotherapy led to an improvement in progression-free survival compared with neoadjuvant chemotherapy alone in newly diagnosed patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

S. Alex Mastroyannis, MD, MSCE, discusses the administration and role of hyperthermic intraperitoneal chemotherapy in ovarian cancer, as well as its benefit for patients in the phase 3 OVHIPEC-1 trial.

Mary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

The FDA has granted fast track designation to IDE161 for the treatment of adult patients with advanced or metastatic ovarian cancer harboring germline or somatic BRCA1/2 mutations who are platinum resistant and have received prior treatment with antiangiogenic and PARP inhibitor therapies.

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.

Martin Cannon, PhD, discusses the use of dendritic cell vaccines and immune checkpoint inhibitors in ovarian cancer.